Beyond Trial-and-Error: Self-Optimizing LC Workflows

Pharmaceutical development is increasingly adopting faster, more reliable analytical approaches that reduce development time, costs, waste, and environmental impact while improving efficiency in both R&D and commercial testing. The industry’s long-term goal is highly automated, data-driven manufacturing with real-time quality monitoring that minimizes the need for traditional end-product testing. Advances in AI, automation, digital technologies, and predictive modeling are reducing reliance on trial-and-error experimentation while improving precision and lowering material and solvent use. Examples include using near-infrared spectroscopy (NIR) in place of some ultrahigh performance liquid chromatography (UHPLC) methods, replacing animal-based microbiological tests with alternative approaches, and using computer models to predict drug dissolution behavior. Together, these innovations are transforming analytical laboratories by accelerating development, supporting sustainability, and maintaining the scientific rigor required for regulatory compliance.

In the first of a four-part interview taken at analytica 2026, Koen Vanhoutte of Johnson & Johnson Innovative Medicine discusses how self‑optimizing LC workflows are changing the way chromatographic methods are developed compared with traditional trial‑and‑error approaches.

Koen Vanhoutte is an Executive Director in pharmaceutical research and development with more than 25 years of industrial experience in analytical chemistry. He holds a Ph.D. in chemistry from the University of Antwerp, with his early scientific training and core expertise rooted in liquid chromatography–mass spectrometry (LC–MS) and chromatographic method development. Over the course of his career, he has built extensive experience in Chemistry, Manufacturing and Controls (CMC) across both early‑ and late‑stage pharmaceutical development. He currently leads the Synthetics Analytical Development organization within Johnson & Johnson Innovative Medicine, where he is responsible for defining and delivering analytical strategies across the full product lifecycle, from development through commercial manufacture. His scope includes method development, validation, technology transfer, clinical trial material release, and ICH stability testing for synthetic therapeutics. His involvement in biologics is focused specifically on microbiology‑based analytical methods, and he has extensive experience supporting global regulatory submissions and inspections, including interactions with FDA and EMA. Vanhoutte is passionate about leading and developing global teams and fostering scientific excellence through people development. He is strongly committed to applying rigorous analytical science to advance therapeutic development, while staying closely connected to evolving analytical methodologies through pragmatic, applied innovation.